Thus, IRF5 inhibition protects from hyperinflammation whether induced by viral or bacterial infection, the latter a common complication of acute respiratory distress syndrome, although its incidence in COVID-19 is only just being investigated (71–73, 184). Here, IRF5 is linked to COVID-19.